Incidence of newly diagnosed diabetes after Covid-19
Tóm tắt
The aim of this work was to investigate diabetes incidence after infection with coronavirus disease-2019 (Covid-19). Individuals with acute upper respiratory tract infections (AURI), which are frequently caused by viruses, were selected as a non-exposed control group. We performed a retrospective cohort analysis of the Disease Analyzer, which comprises a representative panel of 1171 physicians’ practices throughout Germany (March 2020 to January 2021: 8.8 million patients). Newly diagnosed diabetes was defined based on ICD-10 codes (type 2 diabetes: E11; other forms of diabetes: E12–E14) during follow-up until July 2021 (median for Covid-19, 119 days; median for AURI 161 days). Propensity score matching (1:1) for sex, age, health insurance, index month for Covid-19/AURI and comorbidity (obesity, hypertension, hyperlipidaemia, myocardial infarction, stroke) was performed. Individuals using corticosteroids within 30 days after the index dates were excluded. Poisson regression models were fitted to obtain incidence rate ratios (IRRs) for diabetes. There were 35,865 individuals with documented Covid-19 in the study period. After propensity score matching, demographic and clinical characteristics were similar in 35,865 AURI controls (mean age 43 years; 46% female). Individuals with Covid-19 showed an increased type 2 diabetes incidence compared with AURI (15.8 vs 12.3 per 1000 person-years). Using marginal models to account for correlation of observations within matched pairs, an IRR for type 2 diabetes of 1.28 (95% CI 1.05, 1.57) was estimated. The IRR was not increased for other forms of diabetes. Covid-19 confers an increased risk for type 2 diabetes. If confirmed, these results support the active monitoring of glucose dysregulation after recovery from mild forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Tài liệu tham khảo
Müller JA, Groß R, Conzelmann C et al (2021) SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab 3(2):149–165. https://doi.org/10.1038/s42255-021-00347-1
Sathish T, Tapp RJ, Cooper ME, Zimmet P (2021) Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab 47(2):101204. https://doi.org/10.1016/j.diabet.2020.10.002
Montefusco L, Ben Nasr M, D'Addio F et al (2021) Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab 3(6):774–785. https://doi.org/10.1038/s42255-021-00407-6
Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K (2018) Basic characteristics and representativeness of the German disease analyzer database. Int J Clin Pharmacol Ther 56(10):459–466. https://doi.org/10.5414/CP203320
Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P (2021) Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Obes Metab 23(3):870–874. https://doi.org/10.1111/dom.14269
Schilling J, Tolksdorf K, Marquis A et al (2021) The different periods of COVID-19 in Germany: a descriptive analysis from January 2020 to February 2021. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 64(9):1093–1106. https://doi.org/10.1007/s00103-021-03394-x [article in German]
Ayoubkhani D, Khunti K, Nafilyan V et al (2021) Post-Covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 372:n693. https://doi.org/10.1136/bmj.n693
Daugherty SE, Guo Y, Heath K et al (2021) Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 373:n1098. https://doi.org/10.1136/bmj.n1098
Nalbandian A, Sehgal K, Gupta A et al (2021) Post-acute COVID-19 syndrome. Nat Med 27(4):601–615. https://doi.org/10.1038/s41591-021-01283-z
Suwanwongse K, Shabarek N (2021) Newly diagnosed diabetes mellitus, DKA, and COVID-19: causality or coincidence? A report of three cases. J Med Virol 93(2):1150–1153. https://doi.org/10.1002/jmv.26339